Class: Trace metal
- Injection, solution molybdenum 25 mcg/mL (as ammonium molybdate 46 mcg/mL)
Constituent of the enzymes xanthine oxidase, sulfite oxidase, and aldehyde oxidase.
Primarily excreted by the kidneys, with some excretion also through bile.
Indications and Usage
As a supplement to TPN to help prevent depletion of endogenous stores of molybdenum and subsequent deficiency symptoms.
Do not give undiluted by direct injection into a peripheral vein; not to be given to copper-deficient patients without copper supplementation.
Dosage and AdministrationMolybdenum Deficiency State Resulting From Prolonged TPN Support
IV 163 mcg/day of molybdenum for 21 days has reversed deficiency symptoms in an adult without toxicity.Supplementation in Metabolically Stable Adults Receiving TPN
IV 20 to 120 mcg/day of molybdenum added to the TPN.Children
IV Extrapolate from the adult dosage recommendation.Renal Function Impairment
Adjust or omit dose as needed.Hepatic Function Impairment
Adjust or omit dose as needed in patients with bile duct obstruction.
- Do not give undiluted by direct injection into a peripheral vein.
- Add to TPN solution.
Store between 68° and 77°F.
None well documented.
Adverse reactions are unlikely to occur at the recommended dosage level.
Monitor sulfur and purine metabolism. Frequently monitor blood copper levels because copper and molybdenum are antagonistic to each other.
Category C . Crosses the placenta.
Detected in animal milk.
Primarily excreted by the kidneys; adjust or omit dose as needed.
Some excreted in the bile; adjust or omit dose as needed in patients with bile duct obstruction.
Parenteral products may contain aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk.
Effects on copper
Excessive amounts of molybdenum may produce copper deficiency.
Effects on metabolism
Molybdenum metabolism is inversely related to copper, sulfate ions, tungsten, methionine, and cysteine.
Gout-like syndrome; increased levels of molybdenum, uric acid, and xanthine oxidase.
- Advise patient that medication will be prepared and administered by a health care provider in a hospital setting.
Copyright © 2009 Wolters Kluwer Health.